# A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

> **NCT07040644** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 150 (estimated)

## Conditions studied

- Triple Negative Breast Neoplasms

## Interventions

- **DRUG:** Sacituzumab Govitecan (SG)
- **DRUG:** Toripalimab
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT07040644
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2027-06
- **Final completion:** 2028-06
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07040644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07040644, "A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07040644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*